Analyst: Strong Novo Nordisk outlook should satisfy investors
An analyst has looked over the Danish drugmaker’s annual report, concluding that there are enough elements – including expected 2023 sales growth of up to 19% – for a Novo stock boost.
.jpg)
by marketwire, translated by daniel pedersen
Novo Nordisk’s target of achieving sales growth up to 19% at constant exchange rates (CER) in 2023, with a matching hope for the operating profit, should more than satisfy the market’s expectations, assesses Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk doubles obesity sales in 2022
For subscribers
Novo Nordisk predicts wide range for 2023 sales growth
For subscribers
.jpg&w=384&q=75)
